Similarly, PYY and SERPINA3 associated with an increased risk of early onset prostate cancer only [ORPYY = 1.87, 95% CI: 1.43–2.44; ORSERPINA3 = 2.08, 95% CI: 1.51–2.88, Fig. 2] while C2 associated with aggressive prostate cancer only [ORC2 = 0.67, 95% CI: 0.56–0.81, Fig. 2]. Here, PYY is linked to prostate carcinoma.